No record found
No record found
* Returns not adjusted for payouts
Company Profile
Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited) was incorporated in Pakistan as a public listed company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017) on 31 March 2015. The Company is a subsidiary of ‘Haleon Netherlands B.V’. The ultimate parent of the Company is Haleon plc. The Company is inter alia principally engaged in the manufacturing, marketing and sale of consumer healthcare and over the counter health products.
Farhan Muhammad Haroon | CEO |
Muhammad Zindah Moin Mohajir | Chairperson |
Mashal Mohammad | Company Secretary |
11-A, 11th Floor, Sky Tower (East Wing), Dolmen City, HC-3, Block 4, Scheme-5, Clifton, Karachi, 75600
CDC Share Registrar Services Limited CDC House, Main Shahrah-e-Faisal, Karachi.
M/s KPMG Taseer Hadi & Co. Chartered Accountants
December
Equity Profile
Announcements
Date | Title | Document |
---|---|---|
Oct 30, 2024 | Transmission of Quarterly Report for the Period Ended 30 September 2024 | View PDF |
Oct 24, 2024 | Financial Results for the Period Ended 30 September 2024 | View PDF |
Aug 29, 2024 | Transmission of Half Yearly Report for the Period Ended 30 June 2024 | View PDF |
Aug 22, 2024 | Financial Results for the Quarter Ended 30 June 2024 | View PDF |
Apr 30, 2024 | Transmission of Quarterly Report for the Period Ended 31 March 2024 | View PDF |
Apr 25, 2024 | Financial Results for the Quarter Ended 31 March 2024 | View PDF |
Apr 8, 2024 | Transmission of Annual Report for the Year Ended 2023 | View PDF |
Mar 5, 2024 | Financial Results for the Year Ended 31 December 2023 | View PDF |
Oct 30, 2023 | Transmission of Quarterly Report for the Period Ended 30 September 2023 | View PDF |
Oct 23, 2023 | Financial Results for the Quarter Ended 30 September 2023 | View PDF |
Date | Title | Document |
---|---|---|
Oct 16, 2024 | Notice of Board of Directors Meeting - (Q3-2024) | View PDF |
Aug 13, 2024 | Notice of Board of Directors Meeting - (Q2-2024) | View PDF |
Apr 26, 2024 | CTC of Resolutions Passed in the Annual General Meeting 2023 | View PDF |
Apr 17, 2024 | Notice of Board of Directors Meeting - (Q1-2024) | View PDF |
Apr 8, 2024 | Notice of Annual General Meeting | View PDF |
Apr 4, 2024 | Prior Publication of Annual General Meeting Notice | View PDF |
Feb 26, 2024 | Notice of Board of Directors Meeting - (Q4-2023) | View PDF |
Oct 13, 2023 | Notice of Board of Directors Meeting - (Q3-2023) | View PDF |
Aug 11, 2023 | Notice of Board of Directors Meeting - (Q2-2023) | View PDF |
Apr 27, 2023 | CTC of Resolutions Passed in the Annual General Meeting 2022 | View PDF |
Date | Title | Document |
---|---|---|
Nov 20, 2024 | Presentation for Corporate Briefing Session 2024 | View PDF |
Nov 19, 2024 | Credit of Interim Cash Dividend | View PDF |
Nov 18, 2024 | Prior Publication of Notice of Credit of Interim Cash Dividend | View PDF |
Nov 18, 2024 | Notice of Corporate Briefing Session 2024 | View PDF |
Oct 31, 2024 | Notice of Interim Cash Dividend and Share Book Closure | View PDF |
Oct 30, 2024 | Prior Publication of Notice of Interim Cash Dividend and Share Book Closure | View PDF |
Sep 16, 2024 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View PDF |
Jun 13, 2024 | Reminder for Conversion of Physical Shares to Book Entry Form & Unclaimed Dividend(s) / Share Certificates | View PDF |
Jun 12, 2024 | Prior Publication of Reminder for Conversion of Physical Shares to Book Entry Form & Unclaimed Dividend(s) / Share Certificates | View PDF |
Apr 18, 2024 | Notice of Electronic Voting and Postal Ballot | View PDF |
Financials
All numbers in thousands (000's) except EPS
2023 | 2022 | 2021 | 2020 | |
---|---|---|---|---|
Sales | 31,609,776 | 27,507,212 | 24,163,150 | 19,846,106 |
Profit after Taxation | 995,586 | 325,411 | 2,134,334 | 1,262,009 |
EPS | 8.51 | 2.78 | 18.23 | 10.78 |
Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | |
---|---|---|---|---|
Sales | 9,754,500 | 9,805,213 | 7,953,602 | 8,053,365 |
Profit after Taxation | 1,329,784 | 1,223,459 | 649,281 | 314,291 |
EPS | 11.36 | 10.45 | 5.55 | 2.68 |
Ratios
2023 | 2022 | 2021 | 2020 | |
---|---|---|---|---|
Gross Profit Margin (%) | 20.40 | 17.40 | 27.38 | 26.85 |
Net Profit Margin (%) | 3.15 | 1.18 | 8.83 | 6.36 |
EPS Growth (%) | 206.12 | (84.75) | 69.11 | 0.37 |
PEG | 0.10 | (0.70) | 0.19 | 66.04 |
Payouts
Date | Financial Results | Details | Book Closure |
---|---|---|---|
October 25, 2024 4:20 PM | 30/09/2024(IIIQ) | 50% (i) (D) | 07/11/2024 - 08/11/2024 |